CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 703 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04160988
NCT04160988N/ACompleted

A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus

Acer Being Health Inc.·observational·Posted Nov 13, 2019·Updated Jan 29, 2021

In Brief

An observational study for Diabetic Retinopathy. Completed, enrolled 703 participants across 1 site.

Detailed Summary

This study is to evaluate the clinical performance of VeriSee DR for DR screening from color fundus photography images in patients with diabetes mellitus. The sensitivity and specificity of VeriSee DR's automated image analysis for screening the diabetes retinopathy will be determined.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 13, 2019
Enrollment StartDec 16, 2019
Primary CompletionJan 31, 2020
Study CompletionMay 11, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.6 years ago